Head-To-Head Contrast: Burning Rock Biotech (NASDAQ:BNR) and Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ:ALT – Get Free Report) and Burning Rock Biotech (NASDAQ:BNR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Institutional and Insider Ownership

78.0% of Altimmune shares are held by institutional investors. Comparatively, 30.0% of Burning Rock Biotech shares are held by institutional investors. 1.6% of Altimmune shares are held by company insiders. Comparatively, 30.3% of Burning Rock Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Altimmune and Burning Rock Biotech, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Altimmune 1 1 8 0 2.70
Burning Rock Biotech 1 0 0 0 1.00

Altimmune currently has a consensus target price of $14.33, indicating a potential upside of 916.55%. Given Altimmune’s stronger consensus rating and higher possible upside, research analysts plainly believe Altimmune is more favorable than Burning Rock Biotech.

Profitability

This table compares Altimmune and Burning Rock Biotech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Altimmune N/A -29.26% -25.48%
Burning Rock Biotech -13.60% -12.98% -8.59%

Volatility and Risk

Altimmune has a beta of 0.16, indicating that its stock price is 84% less volatile than the S&P 500. Comparatively, Burning Rock Biotech has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.

Valuation and Earnings

This table compares Altimmune and Burning Rock Biotech”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Altimmune $40,000.00 6,859.30 -$88.09 million ($0.72) -1.96
Burning Rock Biotech $77.16 million 1.82 -$7.92 million ($0.87) -15.31

Burning Rock Biotech has higher revenue and earnings than Altimmune. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Summary

Altimmune beats Burning Rock Biotech on 8 of the 14 factors compared between the two stocks.

About Altimmune

(Get Free Report)

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.

About Burning Rock Biotech

(Get Free Report)

Burning Rock Biotech is a precision oncology company that develops and provides next-generation sequencing tests for cancer. Its testing uses tissue and blood samples to help inform treatment decisions, monitor disease and support cancer research. The company also provides research and clinical-trial services to pharmaceutical companies, including support for the development of cancer therapies and diagnostic tests. Burning Rock is headquartered in Guangzhou, China, and its business primarily serves the Chinese healthcare and life sciences markets.

Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.